The CPO title, distinct from a Chief Scientific Officer, signifies a long-term strategy. It focuses on continually developing new technologies within the company, aiming to build an enduring institution rather than a single-asset biotech designed for acquisition.
Many biotechs start with a single technology to solve a single problem. Dispatch Bio's co-founders believed a superior company could be created with a suite of technologies that addresses numerous field observations at once, creating a more robust therapeutic platform.
Instead of the traditional one-way flow of technology from academia to industry, Lex Johnson advocates for a reciprocal relationship. Industry leaders can educate university faculty and tech transfer offices on the practical realities of drug development, making future spinouts more efficient and viable.
Dispatch Bio's co-founder argues that while Philadelphia lacks a dense VC scene, this is not a barrier. Capital is highly portable, as shown by their West Coast investors. The real challenge is persuading local Philadelphia capital (PE, hedge funds) to shift from late-stage to riskier, early-stage biotech investments.
While honors like "Emerging Company of the Year" are motivating, Dispatch Bio's co-founder views the recognition as an added set of responsibilities and expectations. The external awareness creates a healthy pressure to maintain a high level of execution, transforming an award from a simple honor into a performance driver.